Todd M Cooper1, Michael J Absalon2, Todd A Alonzo3, Robert B Gerbing4, Kasey J Leger1, Betsy A Hirsch5, Jessica Pollard6, Bassem I Razzouk7, Richard Aplenc8, E Anders Kolb9. 1. Department of Hematology/Oncology, Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA. 2. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 3. Department of Preventive Medicine, University of Southern California, Los Angeles, CA. 4. Children's Oncology Group, Monrovia, CA. 5. University of Minnesota, Minneapolis, MN. 6. Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA. 7. Peyton Manning Children's Hospital at St Vincent, Indianapolis, IN. 8. Children's Hospital of Philadelphia, Philadelphia, PA. 9. Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE.
Abstract
PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after up to 2 cycles of therapy. PATIENTS AND METHODS: Children > 1 and ≤ 21 years of age with relapsed/refractory AML were eligible for dose finding; those in first relapse were eligible for the efficacy phase. Dose-limiting toxicity (DLT) assessment occurred during cycle 1. Two cycles of therapy were offered (cycle 1: CPX-351; cycle 2: FLAG [fludarabine 30 mg/m2/dose on days 1-5; cytarabine 2,000 mg/m2/dose on days 1-5; and granulocyte-colony stimulating factor 5 µg/kg/dose, days 1-5 and day 15 through absolute neutrophil count > 500/µL]). Response was assessed after each cycle. RESULTS: Thirty-eight patients enrolled: 6 in the dose-finding phase and 32 in the efficacy phase. During dose finding, 1/6 patients experienced a DLT (grade 3 decrease in ejection fraction). The RP2D was 135 units/m2 on days 1, 3, and 5. Toxicities of grade ≥ 3 during cycle 1 included fever/neutropenia (45%), infection (47%), and rash (40%). There was no toxic mortality. Best responses included 20 complete response (CR; 54%), 5 CR with partial recovery of platelet count (CRp; 14%), and 5 CR with incomplete blood count recovery (14%). Twenty-one of 25 with CR/CRp had no detectable residual disease (RD; 84%) by flow cytometry. Hematopoietic stem cell transplantation (HSCT) was used as consolidation in 29/30 responders (96.7%); 20/25 (80%) had no RD before HSCT. CONCLUSION: The RP2D of CPX-351 is 135 units/m2/dose on days 1, 3, and 5. Toxicity was manageable, and protocol therapy was effective. Response rates are superior to prior published North American cooperative group clinical trials for children with AML in first relapse.
PURPOSE: Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after up to 2 cycles of therapy. PATIENTS AND METHODS: Children > 1 and ≤ 21 years of age with relapsed/refractory AML were eligible for dose finding; those in first relapse were eligible for the efficacy phase. Dose-limiting toxicity (DLT) assessment occurred during cycle 1. Two cycles of therapy were offered (cycle 1: CPX-351; cycle 2: FLAG [fludarabine 30 mg/m2/dose on days 1-5; cytarabine 2,000 mg/m2/dose on days 1-5; and granulocyte-colony stimulating factor 5 µg/kg/dose, days 1-5 and day 15 through absolute neutrophil count > 500/µL]). Response was assessed after each cycle. RESULTS: Thirty-eight patients enrolled: 6 in the dose-finding phase and 32 in the efficacy phase. During dose finding, 1/6 patients experienced a DLT (grade 3 decrease in ejection fraction). The RP2D was 135 units/m2 on days 1, 3, and 5. Toxicities of grade ≥ 3 during cycle 1 included fever/neutropenia (45%), infection (47%), and rash (40%). There was no toxic mortality. Best responses included 20 complete response (CR; 54%), 5 CR with partial recovery of platelet count (CRp; 14%), and 5 CR with incomplete blood count recovery (14%). Twenty-one of 25 with CR/CRp had no detectable residual disease (RD; 84%) by flow cytometry. Hematopoietic stem cell transplantation (HSCT) was used as consolidation in 29/30 responders (96.7%); 20/25 (80%) had no RD before HSCT. CONCLUSION: The RP2D of CPX-351 is 135 units/m2/dose on days 1, 3, and 5. Toxicity was manageable, and protocol therapy was effective. Response rates are superior to prior published North American cooperative group clinical trials for children with AML in first relapse.
Authors: Eric J Feldman; Jeffrey E Lancet; Jonathan E Kolitz; Ellen K Ritchie; Gail J Roboz; Alan F List; Steven L Allen; Ekatherine Asatiani; Lawrence D Mayer; Christine Swenson; Arthur C Louie Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Michael S Ewer; Francis J Martin; Craig Henderson; Charles L Shapiro; Robert S Benjamin; Alberto A Gabizon Journal: Semin Oncol Date: 2004-12 Impact factor: 4.929
Authors: Kelly D Getz; Lillian Sung; Todd A Alonzo; Kasey J Leger; Robert B Gerbing; Jessica A Pollard; Todd Cooper; E Anders Kolb; Alan S Gamis; Bonnie Ky; Richard Aplenc Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Wah-Seng Lim; Paul G Tardi; Nancy Dos Santos; Xiaowei Xie; Mannie Fan; Barry D Liboiron; Xiaoping Huang; Troy O Harasym; David Bermudes; Lawrence D Mayer Journal: Leuk Res Date: 2010-02-06 Impact factor: 3.156
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: A Rahman; S R Husain; J Siddiqui; M Verma; M Agresti; M Center; A R Safa; R I Glazer Journal: J Natl Cancer Inst Date: 1992-12-16 Impact factor: 13.506
Authors: S Lowis; I Lewis; A Elsworth; C Weston; F Doz; G Vassal; R Bellott; J Robert; F Pein; S Ablett; R Pinkerton; D Frappaz Journal: Br J Cancer Date: 2006-08-01 Impact factor: 7.640
Authors: Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D'Amico; Giuseppina De Simone; Rosanna Cuccurullo; William G Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro Journal: Biomedicines Date: 2022-06-14
Authors: Jeffrey J Bednarski; Clare Zimmerman; Melissa M Berrien-Elliott; Jennifer A Foltz; Michelle Becker-Hapak; Carly C Neal; Mark Foster; Timothy Schappe; Ethan McClain; Patrick P Pence; Sweta Desai; Samantha Kersting-Schadek; Pamela Wong; David A Russler-Germain; Bryan Fisk; Wen-Rong Lie; Jeremy Eisele; Stephanie Hyde; Sima T Bhatt; Obi L Griffith; Malachi Griffith; Allegra A Petti; Amanda F Cashen; Todd A Fehniger Journal: Blood Date: 2022-03-17 Impact factor: 25.476
Authors: Yixin Hu; Kenneth J Caldwell; Mihaela Onciu; Sara M Federico; Marta Salek; Sara Lewis; Shaohua Lei; Jinghui Zhang; Kim E Nichols; Clifford M Takemoto; Brandon M Triplett; Jason E Farrar; Jeffrey E Rubnitz; Raul C Ribeiro; Marcin W Wlodarski Journal: Blood Adv Date: 2022-01-25
Authors: Neel S Bhatt; Malek J Baassiri; Wei Liu; Nickhill Bhakta; Wassim Chemaitilly; Matthew J Ehrhardt; Hiroto Inaba; Kevin Krull; Kirsten K Ness; Jeffrey E Rubnitz; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Leukemia Date: 2021-01-25 Impact factor: 11.528